Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis-Reference-Cited by-同舟云学术

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Published:2017-11-28 Issue:12 Volume:69 Page:2370-2379
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Denton Christopher P.¹,Hachulla Éric²,Riemekasten Gabriela³,Schwarting Andreas⁴,Frenoux Jean-Marie⁵,Frey Aline⁵,Le Brun Franck-Olivier⁵,Herrick Ariane L.⁶,

Affiliation:

1. Royal Free Hospital; London UK

2. National Referral Centre for Rare Systemic Auto-immune Diseases; Department of Internal Medicine; Hôpital Huriez; University of Lille; Lille France

3. Charité University of Medicine; Berlin Germany

4. Johannes Gutenberg University; Mainz, and ACURA Rheumatology Centre RLP; Bad Kreuznach Germany

5. Actelion Pharmaceuticals Ltd.; Allschwil Switzerland

6. The University of Manchester; Salford Royal NHS Foundation Trust and NIHR Manchester Musculoskeletal Biomedical Research Centre; Central Manchester NHS Foundation Trust; Manchester Academic Health Science Centre; Manchester UK

Funder

Actelion Pharmaceuticals

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.40242/fullpdf

Reference45 articles.

1. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database;Meier;Ann Rheum Dis,2012

2. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis;Hughes;Rheumatology (Oxford),2015

3. Management of Raynaud Phenomenon and digital ulcers in scleroderma;Cappelli;Rheum Dis Clin North Am,2015